Drug Profile
Research programme: antibacterials - Novexel
Alternative Names: AVE 2221A; AVE 6971; AVE 6971A; NXL 105Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Novexel; sanofi-aventis
- Developer Novexel
- Class Quinolines
- Mechanism of Action Cell wall inhibitors; DNA topoisomerase inhibitors; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections; Pseudomonal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Nosocomial-infections in France